As mentioned above, blocking TGF-β and CTLA-4 simultaneously in mouse models of castration-resistant prostate cancer with bone metastasis significantly inhibited the progression of bone metastasis and improved the overall survival rate compared with CTLA-4 inhibitor monotherapy [48]. The gene discussed is TGFB1; the disease is prostate carcinoma.